NZ595770A - N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors - Google Patents

N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors

Info

Publication number
NZ595770A
NZ595770A NZ595770A NZ59577007A NZ595770A NZ 595770 A NZ595770 A NZ 595770A NZ 595770 A NZ595770 A NZ 595770A NZ 59577007 A NZ59577007 A NZ 59577007A NZ 595770 A NZ595770 A NZ 595770A
Authority
NZ
New Zealand
Prior art keywords
condition
disease
nitroxyl donors
physiologically useful
new physiologically
Prior art date
Application number
NZ595770A
Other languages
English (en)
Inventor
Stephen Martin Courtney
Vincent Jacob Kalish
Frederick Arthur Brookfield
Andrew D Cohen
Original Assignee
Univ Johns Hopkins
Cardioxyl Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38284031&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ595770(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Johns Hopkins, Cardioxyl Pharmaceuticals Inc filed Critical Univ Johns Hopkins
Priority to NZ609381A priority Critical patent/NZ609381A/en
Publication of NZ595770A publication Critical patent/NZ595770A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/67—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfonamide groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/84—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
NZ595770A 2006-03-17 2007-03-16 N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors NZ595770A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ609381A NZ609381A (en) 2006-03-17 2007-03-16 N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78355606P 2006-03-17 2006-03-17
PCT/US2007/006710 WO2007109175A1 (en) 2006-03-17 2007-03-16 N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors

Publications (1)

Publication Number Publication Date
NZ595770A true NZ595770A (en) 2013-04-26

Family

ID=38284031

Family Applications (4)

Application Number Title Priority Date Filing Date
NZ570971A NZ570971A (en) 2006-03-17 2007-03-16 N-Hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
NZ700984A NZ700984A (en) 2006-03-17 2007-03-16 N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
NZ595770A NZ595770A (en) 2006-03-17 2007-03-16 N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
NZ609381A NZ609381A (en) 2006-03-17 2007-03-16 N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors

Family Applications Before (2)

Application Number Title Priority Date Filing Date
NZ570971A NZ570971A (en) 2006-03-17 2007-03-16 N-Hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
NZ700984A NZ700984A (en) 2006-03-17 2007-03-16 N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ609381A NZ609381A (en) 2006-03-17 2007-03-16 N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors

Country Status (24)

Country Link
US (11) US8030356B2 (enExample)
EP (8) EP2596785A1 (enExample)
JP (4) JP5548869B2 (enExample)
KR (7) KR20150091427A (enExample)
CN (4) CN103435524B (enExample)
AU (4) AU2007227457B2 (enExample)
BR (1) BRPI0708804B8 (enExample)
CA (1) CA2645988C (enExample)
CY (3) CY1115314T1 (enExample)
DK (2) DK2489350T3 (enExample)
ES (4) ES2448807T3 (enExample)
HU (2) HUE029309T2 (enExample)
IL (3) IL193839A (enExample)
LT (1) LT2586435T (enExample)
MX (3) MX342895B (enExample)
NO (2) NO342523B1 (enExample)
NZ (4) NZ570971A (enExample)
PL (3) PL2586434T3 (enExample)
PT (3) PT2489350E (enExample)
RU (2) RU2616292C2 (enExample)
SG (2) SG170737A1 (enExample)
SI (3) SI2586434T1 (enExample)
TR (1) TR200807066T1 (enExample)
WO (1) WO2007109175A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2613477C (en) * 2005-06-23 2013-12-03 Johns Hopkins University Thiol-sensitive positive inotropes
PT2489350E (pt) 2006-03-17 2014-03-10 Univ Johns Hopkins Med Derivados de n-hidroxilsulfonamida como novos dadores de nitroxilo fisiologicamente úteis
JP2011502105A (ja) * 2007-09-26 2011-01-20 ジョンズ ホプキンス ユニバーシティ 新規で生理学的に有用なニトロキシル供与体としてのｎ−ヒドロキシルスルホンアミド誘導体
EP3067352A3 (en) 2008-05-07 2016-10-19 Cardioxyl Pharmaceuticals Inc. Novel nitroso compounds as nitroxyl donors and methods of use thereof
WO2010105081A1 (en) * 2009-03-13 2010-09-16 Medtronic, Inc. Method of treating heart failure
WO2011063339A1 (en) 2009-11-23 2011-05-26 Cardioxyl Pharmaceuticals, Inc. Nitroxyl donors for the treatment of pulmonary hypertension
CN102753520B (zh) * 2009-12-07 2016-06-08 约翰斯霍普金斯大学 N-酰氧基磺酰胺和n-羟基-n-酰基磺酰胺衍生物
WO2011071947A2 (en) 2009-12-07 2011-06-16 Johns Hopkins University Bis-acylated hydroxylamine derivatives
US9181213B2 (en) * 2011-10-17 2015-11-10 The Johns Hopkins University Meldrum's acid, barbituric acid and pyrazolone derivatives substituted with hydroxylamine as HNO donors
WO2014070919A1 (en) 2012-11-01 2014-05-08 The Johns Hopkins University Controlled hno release through intramolecular cyclization-elimination
BR112015017251B1 (pt) 2013-01-18 2021-10-26 Cardioxyl Pharmaceuticals, Inc. Composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas
EP2764868A1 (en) 2013-02-08 2014-08-13 Friedrich-Alexander-Universität Erlangen-Nürnberg Combination of nitroprusside and a sulfide salt as an HNO-releasing therapeutic for the treatment or prevention of cardiovascular diseases
EP3126329B1 (en) 2014-01-17 2019-05-29 Cardioxyl Pharmaceuticals Inc. N-hydroxymethanesulfonamide nitroxyl donors
US9464061B2 (en) 2014-05-27 2016-10-11 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives
ES2749682T3 (es) 2014-05-27 2020-03-23 Cardioxyl Pharmaceuticals Inc Derivados de pirazolona como donadores de nitroxilo
WO2015183838A1 (en) 2014-05-27 2015-12-03 The Johns Hopkins University N-hydroxylamino-barbituric acid derivatives as nitroxyl donors
ES2871079T3 (es) * 2015-06-26 2021-10-28 Univ Johns Hopkins Acidos hidroxámicos N-sustituidos con grupos salientes a base de carbono como donantes eficaces de HNO y usos de los mismos
EP3365328A1 (en) * 2015-10-19 2018-08-29 Cardioxyl Pharmaceuticals, Inc. Pyrazolone derivatives as nitroxyl donors
WO2017070084A1 (en) * 2015-10-19 2017-04-27 Cardioxyl Pharmaceuticals, Inc. N-hydroxylsulfonamide derivatives as nitroxyl donors
CN109071494B (zh) 2016-03-31 2021-02-12 住友化学株式会社 杂环化合物
EP3490975B1 (en) 2016-07-28 2021-05-05 The Johns Hopkins University O-substituted hydroxamic acids
EP3565544A1 (en) 2017-01-03 2019-11-13 Cardioxyl Pharmaceuticals Inc. Method of administering nitroxyl donating compounds
WO2020182076A1 (zh) 2019-03-08 2020-09-17 南京药捷安康生物科技有限公司 磷酸二酯酶抑制剂的用途
CN114230495B (zh) * 2021-11-24 2023-01-06 海南大学 一种氢化亚硝酰供体及其制备方法
CN114195731A (zh) * 2021-11-24 2022-03-18 海南大学 一种氢化亚硝酰供体化合物及其制备方法
WO2025043108A1 (en) 2023-08-23 2025-02-27 Bristol -Myers S Quibb Company Co-crystals of nitroxyl donating compounds

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1017976A (en) 1911-08-25 1912-02-20 Rudolph Koch Automatic mail-bag catcher and deliverer.
US3751255A (en) * 1972-03-24 1973-08-07 Eastman Kodak Co Photosensitive and thermosensitive element, composition and process
JPS567710A (en) 1979-06-28 1981-01-27 Sansho Seiyaku Kk Whitening cosmetic
US4539321A (en) 1981-10-26 1985-09-03 William H. Rorer, Inc. 5-Diaza-aryl-3-substituted pyridone compounds
DE3583799D1 (de) 1985-01-11 1991-09-19 Abbott Lab Ltd Feste zubereitung mit langsamer freisetzung.
US4663351A (en) 1985-08-23 1987-05-05 Berlex Laboratories, Inc. Dobutamine tri-isobutyric acid ester and the use thereof as a cardiotonic agent
US4798824A (en) 1985-10-03 1989-01-17 Wisconsin Alumni Research Foundation Perfusate for the preservation of organs
JPH01221371A (ja) * 1988-02-29 1989-09-04 Hokko Chem Ind Co Ltd 環状オキシアミン誘導体の製造方法
JPH01221372A (ja) 1988-03-01 1989-09-04 Hokko Chem Ind Co Ltd 環状アシルヒドロキシルアミン誘導体
JPH0221372A (ja) 1988-07-08 1990-01-24 Sharp Corp はんだ付検査装置
JPH0446169A (ja) * 1990-06-14 1992-02-17 Mitsubishi Petrochem Co Ltd 新規なベンゾフラン誘導体及びそれを含有する除草剤
JP2773959B2 (ja) 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
JPH04321671A (ja) * 1991-04-17 1992-11-11 Mitsubishi Petrochem Co Ltd カルバモイルトリアゾール誘導体およびそれを有効成分とする除草剤
JP2728357B2 (ja) * 1992-10-28 1998-03-18 塩野義製薬株式会社 ベンジリデン誘導体
DE69301894T2 (de) 1992-10-28 1996-11-07 Shionogi & Co Benzylidenderivate
JPH09165365A (ja) * 1995-09-27 1997-06-24 Ono Pharmaceut Co Ltd スルホンアミド誘導体
JPH10142729A (ja) * 1996-11-05 1998-05-29 Fuji Photo Film Co Ltd 熱現像画像記録材料
US6525081B1 (en) * 1997-10-24 2003-02-25 Shionogi & Co., Ltd. Antirheumatic
AU9645798A (en) * 1997-10-24 1999-05-17 Shionogi & Co., Ltd. Antiulcerative
HRP20020585B1 (hr) * 1997-11-12 2013-02-28 Bayer Schering Pharma Aktiengesellschaft 2-fenil supstituirani imidazotriazinoni kao inhibitori fosfodiesteraze
UA73092C2 (uk) 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
WO2000006128A1 (fr) 1998-07-28 2000-02-10 Tanabe Seiyaku Co., Ltd. Preparation capable de liberer un medicament au niveau d'un site cible dans l'intestin
LT4727B (lt) 1998-12-29 2000-11-27 Jonas Šarlauskas 5-pakeisti sulfamoilbenzimidazol-2-ilkarbamino rūgščių metilo esteriai, turintys antihelmintinį aktyvumą
WO2000042002A1 (en) * 1999-01-13 2000-07-20 Warner-Lambert Company Sulphohydroxamic acids and sulphohydroxamates and their use as mek inhibitors
GB9918684D0 (en) * 1999-08-09 1999-10-13 Novartis Ag Organic compounds
WO2001016094A1 (de) * 1999-09-01 2001-03-08 Aventis Pharma Deutschland Gmbh Sulfonylcarboxamidderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
JP2002072459A (ja) 2000-08-28 2002-03-12 Toyo Gosei Kogyo Kk 光酸発生剤及びそれを含有する感光性樹脂組成物
GB0114223D0 (en) 2001-06-12 2001-08-01 Ici Plc Catalytic oxidation process
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) * 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
US20040121399A1 (en) 2002-12-20 2004-06-24 International Business Machines Corporation Substrate bound linker molecules for the construction of biomolecule microarrays
AU2004266658A1 (en) 2003-08-12 2005-03-03 3M Innovative Properties Company Hydroxylamine substituted imidazo-containing compounds
CA2545825A1 (en) * 2003-11-14 2005-06-02 3M Innovative Properties Company Hydroxylamine substituted imidazo ring compounds
JP2007514759A (ja) * 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
EP1718621A4 (en) * 2004-01-30 2009-08-19 Univ Johns Hopkins NITROXYL PREPARATION COMPOUNDS APPLICATION METHOD
US8168771B2 (en) 2005-01-31 2012-05-01 The Johns Hopkins University Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants
CA2613477C (en) 2005-06-23 2013-12-03 Johns Hopkins University Thiol-sensitive positive inotropes
PT2489350E (pt) 2006-03-17 2014-03-10 Univ Johns Hopkins Med Derivados de n-hidroxilsulfonamida como novos dadores de nitroxilo fisiologicamente úteis
JP2011502105A (ja) 2007-09-26 2011-01-20 ジョンズ ホプキンス ユニバーシティ 新規で生理学的に有用なニトロキシル供与体としてのｎ−ヒドロキシルスルホンアミド誘導体
BR112015017251B1 (pt) 2013-01-18 2021-10-26 Cardioxyl Pharmaceuticals, Inc. Composições farmacêuticas compreendendo doadores de nitroxil, misturas e usos das referidas composições farmacêuticas

Also Published As

Publication number Publication date
NO343986B1 (no) 2019-08-05
JP5548869B2 (ja) 2014-07-16
ES2576292T3 (es) 2016-07-06
CN109438298B (zh) 2021-10-08
AU2017221796B2 (en) 2019-10-03
AU2016201037A1 (en) 2016-03-10
EP2586435B1 (en) 2016-09-14
CN101472576A (zh) 2009-07-01
SG10201503828QA (en) 2016-10-28
AU2013201667A1 (en) 2013-04-11
US20180244610A1 (en) 2018-08-30
BRPI0708804B8 (pt) 2021-05-25
USRE45314E1 (en) 2014-12-30
DK2489350T3 (en) 2014-03-03
TR200807066T1 (tr) 2009-11-23
KR20140147155A (ko) 2014-12-29
EP2489350B1 (en) 2013-12-04
CN103435524A (zh) 2013-12-11
EP3693363A1 (en) 2020-08-12
IL217739A0 (en) 2012-03-29
DK2586435T3 (en) 2017-01-09
PL2489350T3 (pl) 2014-08-29
US8030356B2 (en) 2011-10-04
EP2596785A1 (en) 2013-05-29
SI2586434T1 (sl) 2016-09-30
JP2009530303A (ja) 2009-08-27
LT2586435T (lt) 2016-12-12
US20170022154A1 (en) 2017-01-26
WO2007109175A1 (en) 2007-09-27
MX342895B (es) 2016-10-18
KR101595781B1 (ko) 2016-02-19
PL2586435T3 (pl) 2017-06-30
JP2017057190A (ja) 2017-03-23
RU2616292C2 (ru) 2017-04-14
EP3124471A1 (en) 2017-02-01
EP1998761A1 (en) 2008-12-10
CA2645988C (en) 2017-01-10
MX368352B (es) 2019-09-30
HUE030920T2 (en) 2017-06-28
EP2586434A1 (en) 2013-05-01
HK1179509A1 (en) 2013-10-04
US20210053915A1 (en) 2021-02-25
JP5764590B2 (ja) 2015-08-19
NZ700984A (en) 2016-05-27
ES2811258T3 (es) 2021-03-11
AU2017221796A1 (en) 2017-09-21
JP2015096525A (ja) 2015-05-21
HK1174531A1 (en) 2013-06-14
ES2600518T3 (es) 2017-02-09
EP2586435A1 (en) 2013-05-01
NO20180624A1 (no) 2008-12-11
PL2586434T3 (pl) 2016-10-31
NO20084355L (no) 2008-12-11
SG170737A1 (en) 2011-05-30
EP2586434B1 (en) 2016-04-27
KR20140041941A (ko) 2014-04-04
MX2008011643A (es) 2009-02-10
CN104672115B (zh) 2018-11-23
IL193839A (en) 2015-04-30
US20200087253A1 (en) 2020-03-19
ES2448807T3 (es) 2014-03-17
IL238271A (en) 2017-05-29
EP2586433A1 (en) 2013-05-01
KR102011703B1 (ko) 2019-08-19
CN104672115A (zh) 2015-06-03
KR20150091427A (ko) 2015-08-10
KR20160128447A (ko) 2016-11-07
EP2489350A1 (en) 2012-08-22
CN101472576B (zh) 2013-04-17
AU2007227457A1 (en) 2007-09-27
CY1115314T1 (el) 2017-01-04
KR101473718B1 (ko) 2014-12-17
JP2013144686A (ja) 2013-07-25
US20140336396A1 (en) 2014-11-13
RU2008141151A (ru) 2010-04-27
CN103435524B (zh) 2016-02-10
HUE029309T2 (en) 2017-02-28
SI2586435T1 (sl) 2016-12-30
US9969684B2 (en) 2018-05-15
US11306056B2 (en) 2022-04-19
NZ570971A (en) 2011-11-25
BRPI0708804A2 (pt) 2011-06-14
US20160002156A1 (en) 2016-01-07
US10829445B2 (en) 2020-11-10
KR20190096457A (ko) 2019-08-19
US9221780B2 (en) 2015-12-29
AU2016201037B2 (en) 2017-09-14
CY1117844T1 (el) 2017-05-17
CY1118237T1 (el) 2017-06-28
KR101878816B1 (ko) 2018-07-16
KR20180082639A (ko) 2018-07-18
SI2489350T1 (sl) 2014-05-30
IL217739A (en) 2016-09-29
JP6060139B2 (ja) 2017-01-11
US20170305847A1 (en) 2017-10-26
CA2645988A1 (en) 2007-09-27
US20110306614A1 (en) 2011-12-15
US9725410B2 (en) 2017-08-08
US20190144380A1 (en) 2019-05-16
PT2586434T (pt) 2016-08-05
PT2489350E (pt) 2014-03-10
NZ609381A (en) 2014-10-31
KR20090058476A (ko) 2009-06-09
BRPI0708804B1 (pt) 2019-12-17
EP2586434B3 (en) 2022-04-06
ES2576292T7 (es) 2022-08-24
US20070299107A1 (en) 2007-12-27
EP3124471B1 (en) 2020-06-03
US10179765B2 (en) 2019-01-15
US10487049B2 (en) 2019-11-26
CN109438298A (zh) 2019-03-08
NO342523B1 (no) 2018-06-04
US9487498B2 (en) 2016-11-08
RU2448087C2 (ru) 2012-04-20
RU2011152369A (ru) 2013-06-27
KR102144926B1 (ko) 2020-08-14
PT2586435T (pt) 2016-12-27
AU2007227457B2 (en) 2013-03-28

Similar Documents

Publication Publication Date Title
NZ595770A (en) N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors
NO20065456L (no) Substituerte morfolinforbindelser for behandling av sykdommer i sentralnervesystemet
ATE453620T1 (de) Azetidincarboxamid-derivate zur verwendung zur behandlung von cb1-rezeptor-vermittelten krankheiten
NO20062704L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
NO20075134L (no) Bestemte substituerte amider, fremgangsmate for femstilling derav og anvendelse derav
NO20055314D0 (no) 1,2,4-oksadiazolbenzosyreforbindelser og deres anvendelse for nonsense supresjon og behandling av sykdom
NO20070576L (no) Nye hydantionderivater for behandling av obstruktive luftveissykdommer.
JO2282B1 (en) Oxazole derivatives
AU2003301020A1 (en) Isoquinolinone derivatives and their use as therapeutic agents
DE60315674D1 (de) Neue imidazopyridine und ihre verwendung
NO20062689L (no) Azabisykliske heterosykler som modulatorer for kannabinoidreseptorer
DK1697371T3 (da) Azabicykliske heterocykliske forbindelser som cannabinoidreceptormodulatorer
PT1147110E (pt) Derivados de pirazino (aza)-indol
ATE412655T1 (de) Als neue antiangiogene mittel geeignete thienopyridinphenylacetamide und derivate davon
NO20076137L (no) Nye 2-azetidinonderivater og deres anvendelse som kolestrolabsorpsjonsinhibitorer for behandling av hyperlipidemi
GB0413087D0 (en) Therapeutic compounds
NO20072344L (no) Trombineresptorantagonister.
TW200745034A (en) New compounds
NO20076357L (no) Azabicykliske heterocykler som cannabinoid reseptor modulatorer
TW200726462A (en) Benzamide derivatives and uses related thereto
MX2007004637A (es) Sintesis asimetrica de derivados de dihidrobenzofurano.
NO20055143L (no) Doseringsformer innbefattende AG013736
ATE286064T1 (de) Aromatische und heterozyklische derivate von phytosterolen und/oder phytostanolen zur behandlung von gefässkrankheiten
NO20052730L (no) Aminoalkosyindoler som 5-HT6-reseptorligander for behandling av CNS-lidelser
TW200719883A (en) O-desmethylvenlafaxine and bazedoxifene combination product and uses thereof

Legal Events

Date Code Title Description
ERR Error or correction

Free format text: THE MISSING INVENTOR HAS BEEN ADDED (1225881, COHEN, ANDREW D; 3069034, TOSCANO, JOHN P., 18 TREE FARM COURT, GLEN ARM, MARYLAND 21057, US; 3069038, BROOKFIELD, FREDERICK ARTHUR, 114 MILTON PARK, ABINGDON, OXFORDSHIRE OX14 4SA, GB; 3069042, COURTNEY, STEPHEN MARTIN, 114 MILTON PARK, ABINGDON, OXFORDSHIRE OX14 4SA, GB; 3069044, FROST, LISA MARIE, 114 MILTON PARK, ABINGDON, OXFORDSHIRE OX14 4SA, GB; 3069046, KALISH, VINCENT JACOB, 344 DUBOIS ROAD, ANNAPOLIS, MARYLAND 21401, US)

Effective date: 20130415

S23 Proceedings under section 23: mention of inventor as such in patent

Free format text: INVENTOR COHEN, ANDREW D REMOVED

Effective date: 20130418

Free format text: INVENTOR COHEN, ANDREW D. ADDED

Effective date: 20130418

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 16 MAR 2014 BY AJ PARK

Effective date: 20131113

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 16 MAR 2017 BY CPA GLOBAL

Effective date: 20140130

ERR Error or correction

Free format text: THE OWNER HAS BEEN CORRECTED TO 1225878, CARDIOXYL PHARMACEUTICALS, INC., C/- A J PARK, PO BOX 949, WELLINGTON 6140, NZ; 1370290, THE JOHNS HOPKINS UNIVERSITY, 3400 NORTH CHARLES STREET, BALTIMORE, MARYLAND 21218, US

Effective date: 20150407

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2018 BY CPA GLOBAL

Effective date: 20170203

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2019 BY CPA GLOBAL

Effective date: 20180201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2020 BY CPA GLOBAL

Effective date: 20190201

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2021 BY CPA GLOBAL

Effective date: 20200131

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2022 BY CPA GLOBAL

Effective date: 20210128

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 16 MAR 2023 BY CPA GLOBAL

Effective date: 20220205

LAPS Patent lapsed